Bergamot extract (Bergavit®) reduce serum levels of lipids – new study
The recent study investigate the effects of a Bergamot extract on cardio-metabolic parameters, including plasma lipids, atherogenic lipoproteins and subclinical atherosclerosis. This is the first study investigating the effects of Bergamot flavonoids supplementation on cardio-metabolic risk in dyslipidemic subjects.
Eighty subjects (42 men and 38 women, mean age: 55±13 years) with moderate hypercholesterolemia (e.g.,with plasma LDL-cholesterol concentrations between 160 and 190 mg/dl) were included. A Bergamot-derived extract (Bergavit®) was given at a fixed dose daily (150mg of flavonoids, with16% of neoeriocitrin, 47% of neohesperidin and 37% of naringin) for 6 months.
After 6 months, Bergavit®:
- reduced total cholesterol (from 6.6 ± 0.4 to 5.8 ± 1.1 mmol/l, p < 0.0001),
- reduced triglycerides (from 1.8 ± 0.6 to 1.5 ± 0.9 mmol/l, p = 0.0020),
- reduced LDL-cholesterol (from 4.6 ± 0.2 to 3.7 ± 1.0 mmol/l, p < 0.0001),
- HDL- cholesterol increased (from 1.3 ± 0.2 to 1.4 ± 0.4 mmol/l, p < 0.0007).
Bergavit® (Bergamot juice extract) supplementation significantly reduced plasma lipids and improved the lipoprotein profile.
These findings shed a new light on the potential use of Bergamot extract supplements in the prevention and/or reduction of overall cardiometabolic risk.